Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature
Kintor Pharmaceutical, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trialof KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023.
Kintor Pharmaceuticals has completed a Phase II clinical trial investigating KX-826 in males with androgenetic alopecia (AGA). Alongside the announcement, the China-based biotech reported statistically and clinically meaningful results from the trial, which was conducted in the US.
SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.
Kintor Pharmaceutical has reported positive top-line data from the US Phase I clinical trial of its proteolysis targeting chimera (PROTAC) compound, GT20029.